IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Greenleaf Trust

Greenleaf Trust boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 1.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,154 shares of the medical research company’s stock after purchasing an additional 58 shares during the period. Greenleaf Trust’s holdings in IQVIA were worth $730,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC acquired a new stake in shares of IQVIA during the 4th quarter valued at approximately $13,759,000. Schwartz Investment Counsel Inc. grew its stake in IQVIA by 4.1% in the 4th quarter. Schwartz Investment Counsel Inc. now owns 178,690 shares of the medical research company’s stock worth $41,345,000 after acquiring an additional 7,050 shares during the period. Dfpg Investments LLC purchased a new stake in IQVIA in the 4th quarter worth approximately $1,106,000. Sei Investments Co. grew its stake in IQVIA by 20.2% in the 3rd quarter. Sei Investments Co. now owns 94,748 shares of the medical research company’s stock worth $18,641,000 after acquiring an additional 15,913 shares during the period. Finally, Duality Advisers LP purchased a new stake in IQVIA in the 3rd quarter worth approximately $491,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Activity at IQVIA

In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the transaction, the insider now owns 20,836 shares in the company, valued at approximately $5,031,894. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the transaction, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,285 shares of company stock worth $10,331,003. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Stock Performance

NYSE:IQV opened at $228.09 on Monday. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $41.40 billion, a price-to-earnings ratio of 31.29, a PEG ratio of 2.21 and a beta of 1.50. The firm’s fifty day simple moving average is $244.82 and its 200 day simple moving average is $222.04. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73.

IQVIA (NYSE:IQV) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.02. The business had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The business’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.54 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. Evercore ISI lifted their price target on shares of IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a report on Thursday, February 15th. UBS Group lifted their price target on shares of IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a report on Thursday, February 15th. BTIG Research assumed coverage on shares of IQVIA in a report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price target on the stock. Finally, Truist Financial lifted their price target on shares of IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $256.80.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.